The number of major distributors represents the percentage of revenue.

No definition available.

Name:	jagx_ConcentrationRiskNumberOfDistributors
Namespace Prefix:	jagx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the number of suppliers as a concentration risk.

+ References

No definition available.

+ Details

Name:	jagx_ConcentrationRiskNumberOfSuppliers
Namespace Prefix:	jagx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Threshold used for calculating concentration risk percentage.

+ References

No definition available.

+ Details

Name:	jagx_ThresholdUsedForCalculatingConcentrationOfRisk
Namespace Prefix:	jagx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 954
-SubTopic 310
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481027/954-310-50-2

+ Details

Name:	us-gaap_ConcentrationRiskLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-21

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-20

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-18

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-20

+ Details

Name:	us-gaap_ConcentrationRiskPercentage1
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_MajorCustomersAxis=jagx_CustomerOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_MajorCustomersAxis=jagx_CustomerTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_MajorCustomersAxis=jagx_CustomerThreeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_MajorCustomersAxis=jagx_ThreeMajorPharmaceuticalDistributorsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Summary of Significant Accounting Policies - Accounts receivable and Concentrations (Details)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023 item Distributor	Sep. 30, 2022 Distributor	Dec. 31, 2022
Supplier risk
Concentrations
Number of suppliers \| item			2
Total net revenue \| Customer risk \| Customer 1
Concentrations
Concentration risk (as a percentage)	27.00%		27.00%
Total net revenue \| Customer risk \| Customer 2
Concentrations
Concentration risk (as a percentage)	55.00%	38.00%	53.00%	35.00%
Total net revenue \| Customer risk \| Customer 3
Concentrations
Concentration risk (as a percentage)		54.00%		53.00%
Total net revenue \| Customer risk \| Three major pharmaceutical distributors
Concentrations
Number of major distributors \| Distributor			3	3
Total net revenue \| Customer risk \| Minimum
Concentrations
Threshold for calculating concentration risk percentage			10.00%	10.00%
Total accounts receivable \| Customer risk \| Customer 2
Concentrations
Concentration risk (as a percentage)			29.00%		38.00%
Total accounts receivable \| Customer risk \| Customer 3
Concentrations
Concentration risk (as a percentage)			55.00%		55.00%